Mirum Pharmaceuticals Inc (STU:08D)
€ 38.8 0.6 (1.57%) Market Cap: 1.92 Bil Enterprise Value: 1.95 Bil PE Ratio: 0 PB Ratio: 8.72 GF Score: 52/100

Q3 2022 Mirum Pharmaceuticals Inc Earnings Call Transcript

Nov 09, 2022 / 01:00PM GMT
Release Date Price: €23.4
Operator

Hello, everyone, and welcome to the Mirum Q3 2022 Business Update. My name is Emily, and I'll be coordinating your call today. (Operator Instructions) I'll now turn the call over to our host, Ian Clements, CFO of Mirum. Please go ahead, Ian.

Ian Clements
Mirum Pharmaceuticals, Inc. - CFO

Thanks, Emily, and good morning, everyone. I'd like to welcome you to Mirum Pharmaceuticals Third Quarter 2022 Conference Call. I'm joined today by our President and CEO, Chris Peetz, our Chief Operating Officer, Peter Radovich, our Head of R&D, Pam Vig, and Professor Richard Thompson from King's College London.

Earlier this morning, Mirum issued a news release announcing the company's results for the third quarter of 2022. Copies of this news release and SEC filings can be found in the Investors Section of our website.

Given that we have Professor Thompson on the call today to discuss the exciting full results from our Phase III MARCH-PFIC Study as presented earlier this week at AASLD, we intend to keep the rest of our updates brief.

Full

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot